EA202191371A1 - PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING - Google Patents

PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING

Info

Publication number
EA202191371A1
EA202191371A1 EA202191371A EA202191371A EA202191371A1 EA 202191371 A1 EA202191371 A1 EA 202191371A1 EA 202191371 A EA202191371 A EA 202191371A EA 202191371 A EA202191371 A EA 202191371A EA 202191371 A1 EA202191371 A1 EA 202191371A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
obtaining
polymer compound
solid dispersion
antacid
Prior art date
Application number
EA202191371A
Other languages
Russian (ru)
Inventor
Ацуси Кано
Со Тойонага
Original Assignee
Фуджифилм Корпорэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фуджифилм Корпорэйшн filed Critical Фуджифилм Корпорэйшн
Publication of EA202191371A1 publication Critical patent/EA202191371A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложена фармацевтическая композиция, включающая аморфную твердую дисперсию, содержащую аморфное вещество фармацевтического активного ингредиента, имеющего растворимость в воде 0,1 мг/мл или менее, и кислотное полимерное соединение, и антацид, присутствующий вне аморфной твердой дисперсии, где содержание антацида составляет от 10 до 100 мас.ч. на 100 мас.ч. кислотного полимерного соединения; и способ ее получения.What is proposed is a pharmaceutical composition comprising an amorphous solid dispersion containing an amorphous substance of a pharmaceutical active ingredient having a solubility in water of 0.1 mg/ml or less, and an acidic polymer compound, and an antacid present outside the amorphous solid dispersion, where the antacid content is from 10 to 100 wt.h. per 100 wt.h. acid polymer compound; and how to get it.

EA202191371A 2018-12-14 2019-12-13 PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING EA202191371A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018234689 2018-12-14
PCT/JP2019/049019 WO2020122243A1 (en) 2018-12-14 2019-12-13 Pharmaceutical composition and method for producing same

Publications (1)

Publication Number Publication Date
EA202191371A1 true EA202191371A1 (en) 2021-12-27

Family

ID=71075660

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191371A EA202191371A1 (en) 2018-12-14 2019-12-13 PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING

Country Status (2)

Country Link
EA (1) EA202191371A1 (en)
WO (1) WO2020122243A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4185273A1 (en) * 2020-07-24 2023-05-31 Lonza Bend Inc. Spray drying of supersaturated solutions of api with acetic acid
WO2024024938A1 (en) * 2022-07-29 2024-02-01 大塚製薬株式会社 Delamanid-containing solid dispersion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
ATE537827T1 (en) * 2005-10-31 2012-01-15 Kowa Co PHARMACEUTICAL PREPARATION WITH EXCELLENT PHOTOSTABILITY
GB201006038D0 (en) * 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
JP6184175B2 (en) * 2012-06-05 2017-08-23 第一三共ヘルスケア株式会社 Solid formulation containing loxoprofen sodium and clemastine fumarate
CN106265580B (en) * 2015-05-18 2020-09-08 中国科学院上海药物研究所 SOMCL-9112 solid dispersion, preparation method thereof and SOMCL-9112 solid preparation containing same
JP6961992B2 (en) * 2017-04-26 2021-11-05 ライオン株式会社 Tablets and their manufacturing methods

Also Published As

Publication number Publication date
WO2020122243A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
EA202092003A1 (en) COMPOUNDS FOR TREATMENT OF GENTINGTON'S DISEASE
EA202191371A1 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS OBTAINING
WO2011003853A3 (en) Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
EA201170289A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AT LOW CONCENTRATION OF IMPURITIES
EA200800360A1 (en) FORMS WITH HIGH CONTENT OF DRUGS AND DOSED FORMS
EA200901365A1 (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALIN
TW200724166A (en) Wrinkle-improving agent
MA35411B1 (en) New therapeutic composition containing apomorphine as active ingredient
RU2019118696A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN
EA201690079A1 (en) COMPOSITION CONTAINING GLUTAMINE-N, N-DIOXIDE ACID (GLDA), WATER AND ENZYME
EA201691825A1 (en) STABILIZED SOLUTION ON THE BASIS OF ACTIVE SUBSTANCES, METHOD FOR OBTAINING A STABILIZED SOLUTION OF ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITION ON THE BASIS OF A STABILIZED SOLUTION OF ACTIVE SUBSTANCES (TWO OPTIONS)
WO2009090439A3 (en) Method for stabilization of s-nitrosoglutathione and composition prepared by the same
EA201291422A1 (en) STABLE WATER-CONTAINING PREPARATIONS, INCLUDING BAD SOLUBLE IN WATER, ACTIVE COMPONENTS
EA201791191A1 (en) WATER PHARMACEUTICAL COMPOSITIONS FOR LOCAL APPLICATION IN THE ORAL CAVITY CONTAINING FLURBIPROPHENE AND DEXPANTENOL
MX2021005390A (en) Novel amorphous active pharmaceutical ingredients comprising substantially amorphous mesoporous magnesium carbonate.
EA201592297A1 (en) AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS
RU2017134731A (en) IONACTIVE AQUEOUS SOLUTION BASED ON DISSOLVED INORGANIC SALTS, PREFERREDLY DESIGNED FOR CARE OF THE THROAT
RU2011134414A (en) FULVIC ACID COMBINATION FOR TREATMENT OF VARIOUS CONDITIONS AND DISEASES
EA201270826A1 (en) STABILIZED ACTIVE CONNECTION
RU2013105211A (en) APPLICATION OF TERAPEPTIDE Arg-Pro-Gly-Pro AS A MEANS FOR PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA, METHOD FOR PREVENTION AND TREATMENT OF HYPERCHOLESTEREMIA, PHARMACEUTICAL CHEMISTROSIS
EA202190126A1 (en) COMPOSITION OF CONDENSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVES AND ITS PREPARATION
RU2016112012A (en) LUBRICANT COMPOSITION FOR MOUTH
EA200901205A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ROSIGGITAZONE SALT
EA200701741A1 (en) COMPOSITION CONTAINING OKAPERIDON
PL422140A1 (en) Application of totarol and the totarol-containing pharmaceutical composition